GS 1614
Alternative Names: GS-1614Latest Information Update: 12 Jun 2024
At a glance
- Originator The Scripps Research Institute
- Developer Gilead Sciences; Merck Sharp & Dohme
- Class Alkynes; Antiretrovirals; Fluorinated hydrocarbons; Purine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections